FibroGen (FGEN) sees Significant Insider Selling Continuing

Friday, March 09, 2018 10:15 PM ET

FibroGen (FGEN) sees Significant Insider Selling Continuing

There was a substantial sale of shares of FibroGen by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Rory B Riggs, Director — sold 22,905 shares in the company having a market value of approximately $1,276,954. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 195,472 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 218,377 shares and have averaged 36,396 shares per transaction over this time period.

The number of insider buy/sell trades at FibroGen is greater than that of the 191 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 177 buy/sell trades during this period for an average of 0.9 transactions per company. However, the number of shares traded per transaction by FibroGen insiders is lower than its peers. Within the peer group there were 11,127,908 shares purchased and 6,944,993 shares sold with company insiders acquiring 36,692 shares on average over this time period.

The data sourced in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.